BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

LifeScience Clinical & Diagnostic

China Approves Promega OncoMate MSI Companion Diagnostic For KEYTRUDA Therapy

The National Medical Products Administration (NMPA) has approved the OncoMate® Microsatellite Instability (MSI) Detection Kit as a Class III in vi...

February 06, 2026 | News

Imagion Biosystems Files FDA IND For MagSense Molecular MRI Cancer Imaging Platform

Imagion Biosystems, Ltd. (ASX: IBX) announced that the company has lodged an Investigational New Drug (IND) application with the U.S. Food and Drug Adminis...

February 06, 2026 | News

Lupin Launches Topiramate Extended Release Capsules In The United States

Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced the launch of Topira...

February 06, 2026 | News

Biosion Doses First Patient In Phase 1 Trial Of Novel Anti SIRPα Antibody BSI 082

Milestone validates the clinical potential of BSI-082 as a synergistic combination partner for antibody-drug conjugates (ADCs) and reinforces Biosion's "In...

February 05, 2026 | News

SK bioscience Advances Early Clinical RSV Preventive Monoclonal Antibody Licensed From Gates Medical Research Institute

SK to advance novel early-clinical stage RSV preventive monoclonal antibody in-licensed from Gates Medical Research Institute Exclusive rights to commer...

February 05, 2026 | News

Ascletis Pharma Reports Positive Phase III Safety Results For Denifanstat In Moderate To Severe Acne

Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label ...

February 03, 2026 | News

Turning Frontline Reality Into Policy Action For Cancer Care In Asia

Drawing on her frontline clinical experience in Malaysia, Prof Dr Wan Zamaniah, Consultant Clinical Oncologist, University Malaya Medical Centre&...

February 02, 2026 | Expert Insight

Kazia Therapeutics Advances First In Class Nuclear PD L1 Protein Degrader With Compelling Preclinical Evidence

Kazia Therapeutics (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, announced co...

February 02, 2026 | News

Beckman Coulter Life Sciences And Automata Form Strategic Partnership To Advance AI Ready Lab Automation

Beckman Coulter Life Sciences and Automata announced a strategic partnership that integrates Beckman Coulter Life Sciences liquid handling, genomic and cel...

February 02, 2026 | News

Drug Farm Secures FDA Fast Track Designation For First In Class ALPK1 Inhibitor DF 003 In ROSAH Syndrome

Drug Farm, a clinical-stage biopharmaceutical company advancing two novel small molecule drugs for ROSAH syndrome and hepatitis B, announced that the U.S. ...

January 30, 2026 | News

Skyhawk Therapeutics Reports Positive Nine Month Interim Data For SKY 0515 In Huntington’s Disease

Nine-month findings show mean improvement in Composite Unified Huntington's Disease Rating Scale from baseline of +0.64 points, compared to natural hi...

January 29, 2026 | News

Nuance Pharma’s Ohtuvayre NDA Accepted For Review In China For COPD Maintenance Treatment

Nuance Pharma announced that the National Medical Products Administration (NMPA) of China has officially accepted for review the New Drug Application (NDA)...

January 28, 2026 | News

Innovent’s Tri Specific Antibody IBI3003 Secures US FDA Fast Track Designation In Relapsed Or Refractory Multiple Myeloma

Innovent Biologics, Inc. , a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment...

January 28, 2026 | Report

Merz Therapeutics Submits XEOMIN For Paediatric Spasticity Indication Across Europe

Merz Therapeutics, a leading player in neurology-focused specialty pharma, announced that it has completed the regulatory submission for XEOMIN®&...

January 27, 2026 | News

Stay Connected